IL319844A - Compounds and compositions useful as IAPS inhibitors - Google Patents

Compounds and compositions useful as IAPS inhibitors

Info

Publication number
IL319844A
IL319844A IL319844A IL31984425A IL319844A IL 319844 A IL319844 A IL 319844A IL 319844 A IL319844 A IL 319844A IL 31984425 A IL31984425 A IL 31984425A IL 319844 A IL319844 A IL 319844A
Authority
IL
Israel
Prior art keywords
iaps
inhibitors
compounds
compositions useful
compositions
Prior art date
Application number
IL319844A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tract Pharmaceuticals Inc
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tract Pharmaceuticals Inc, Tufts College filed Critical Tract Pharmaceuticals Inc
Publication of IL319844A publication Critical patent/IL319844A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL319844A 2022-09-29 2023-09-29 Compounds and compositions useful as IAPS inhibitors IL319844A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411550P 2022-09-29 2022-09-29
PCT/US2023/034219 WO2024073106A1 (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of taps

Publications (1)

Publication Number Publication Date
IL319844A true IL319844A (en) 2025-05-01

Family

ID=90479010

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319844A IL319844A (en) 2022-09-29 2023-09-29 Compounds and compositions useful as IAPS inhibitors

Country Status (8)

Country Link
EP (1) EP4593818A1 (de)
JP (1) JP2025535017A (de)
KR (1) KR20250093324A (de)
CN (1) CN120302969A (de)
AU (1) AU2023350829A1 (de)
IL (1) IL319844A (de)
MX (1) MX2025003568A (de)
WO (1) WO2024073106A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090605A1 (en) * 2023-10-24 2025-05-01 University Of Houston System Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19
TW202547480A (zh) * 2024-04-08 2025-12-16 美國休士頓系統大學 可用於治療增殖性疾病或病症之化合物及組合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134679A1 (en) * 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
JP6817288B2 (ja) * 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 新規な連結体及び生体分子と薬物との特異的共役におけるその使用

Also Published As

Publication number Publication date
EP4593818A1 (de) 2025-08-06
AU2023350829A1 (en) 2025-04-03
WO2024073106A8 (en) 2024-11-07
CN120302969A (zh) 2025-07-11
MX2025003568A (es) 2025-07-01
JP2025535017A (ja) 2025-10-22
KR20250093324A (ko) 2025-06-24
WO2024073106A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
IL318748A (en) Compositions and methods for inhibiting KRAS
ZA202210224B (en) Chelator compositions for radiometals and methods of using same
IL319844A (en) Compounds and compositions useful as IAPS inhibitors
IL321319A (en) Compounds and preparations as c-kit kinase inhibitors
IL317736A (en) Compounds as AXL inhibitors
MX2023011014A (es) Inhibidores de heteroarílo de la calicreína plasmática.
IL321357A (en) KIF18A inhibitors and their uses
GB202014160D0 (en) Senolytic compounds and compositions
IL326424A (en) Pharmaceutical compounds and preparations as C-KIT kinase inhibitors
IL304159A (en) A preparation containing bl-8040
IL316934A (en) Compounds and methods for inhibiting MAPT expression
EP4172329A4 (de) Zusammensetzungen zur genomeditierung und verfahren zur verwendung davon
IL300953B1 (en) Compounds and preparations as SPPL2A inhibitors
HK40128730A (en) Compounds and compositions useful as inhibitors of iaps
PT4136091T (pt) Formas e composições de inibidores da calicreína plasmática
EP4294405A4 (de) Zusammensetzungen und verbindungen zur gemeinsamen verabreichung von uridin und ketoleucin
IL317852A (en) 3-βHSD1 inhibitors and compositions and uses thereof
HK40095943A (en) Compounds and compositions as sppl2a inhibitors
CA3273354A1 (en) COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
CA3273357A1 (en) COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
GB202311665D0 (en) Modification of composition
HK40100055A (en) Compositions for and methods of inhibiting sars-cov2 infection
HK40108103A (en) Compositions comprising mixtures of compounds and uses thereof
CA3299146A1 (en) Compositions and methods for inhibiting expression of pd-l1
IL325884A (en) Compositions comprising GAL475 and methods of using them